β¨ Medicine Distribution Consents
2110 NEW ZEALAND GAZETTE, No. 94 25 JUNE 2009
Dosage Form: Dispersible tablet
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Reckitt Benckiser Healthcare (UK) Limited, Hull, North Humberside, United Kingdom
Product: Targin
Active Ingredients: Naloxone hydrochloride dihydrate 5.45mg equivalent to Naloxone hydrochloride anhydrous 5mg
Oxycodone hydrochloride 10mg
Dosage Form: Modified release tablet
New Zealand Sponsor: Mundipharma New Zealand Limited
Manufacturers: Bard Pharmaceuticals Limited, Cambridge, United Kingdom
Mundipharma GmbH, Limburg Lahn, Germany
Product: Targin
Active Ingredients: Naloxone hydrochloride dihydrate 10.9mg equivalent to Naloxone hydrochloride anhydrous 10mg
Oxycodone hydrochloride 20mg
Dosage Form: Modified release tablet
New Zealand Sponsor: Mundipharma New Zealand Limited
Manufacturers: Bard Pharmaceuticals Limited, Cambridge, United Kingdom
Mundipharma GmbH, Limburg Lahn, Germany
Product: Targin
Active Ingredients: Naloxone hydrochloride dihydrate 21.8mg equivalent to Naloxone hydrochloride anhydrous 20mg
Oxycodone hydrochloride 40mg
Dosage Form: Modified release tablet
New Zealand Sponsor: Mundipharma New Zealand Limited
Manufacturers: Bard Pharmaceuticals Limited, Cambridge, United Kingdom
Mundipharma GmbH, Limburg Lahn, Germany
Product: Targin
Active Ingredients: Naloxone hydrochloride dihydrate 2.73mg equivalent to Naloxone hydrochloride anhydrous 2.5mg
Oxycodone hydrochloride 5mg
Dated this 19th day of June 2009.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health
(pursuant to delegation given by the Minister of Health on 6 July 2001).
go5443
Consent to the Distribution of a Changed Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the following new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:
Schedule
Product: BYETTA 10
Active Ingredient: Exenatide 250ΞΌg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturers: Baxter Pharmaceutical Solutions LLC, Bloomington, Indiana, United States of America
Wockhardt UK Limited, Wrexham, United Kingdom
Product: BYETTA 5
Active Ingredient: Exenatide 250ΞΌg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturers: Baxter Pharmaceutical Solutions LLC, Bloomington, Indiana, United States of America
Wockhardt UK Limited, Wrexham, United Kingdom
Dated this 19th day of June 2009.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health
(pursuant to delegation given by the Minister of Health on 6 July 2001).
go5444
Next Page →
β¨ LLM interpretation of page content
π₯ Consent to Distribution of Targin Medicines
π₯ Health & Social Welfare19 June 2009
Medicines, Distribution, Targin, Naloxone, Oxycodone
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health
π₯ Consent to Distribution of BYETTA Medicines
π₯ Health & Social Welfare19 June 2009
Medicines, Distribution, BYETTA, Exenatide
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health
NZ Gazette 2009, No 94